Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer - PubMed (original) (raw)
Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer
S K Baird et al. Oncogene. 2008.
Abstract
Oncolytic adenoviral mutants have considerable activity in ovarian cancer. However, the mechanisms by which they induce cell death remain uncertain. dl922-947, which contains a 24 bp deletion in E1A CR2, is more potent than both E1A wild-type adenoviruses and the E1B-55K deletion mutant dl1520 (Onyx-015). We investigated the mode of death induced by three E1A CR2-deleted replicating adenoviruses in models of ovarian cancer and also the importance of E3 11.6 (adenovirus death protein) in determining this mode of death. Ovarian cancer cells were infected with dl922-947 (E3 11.6+) and dlCR2 (E3 11.6-). We also generated dlCR2 tSmac, which also encodes the gene for processed Smac/DIABLO. Classical apoptosis does not occur in adenoviral cell death and there is no role for mitochondria. Expression of Smac/DIABLO does not enhance cytotoxicity nor increase apoptotic features. A role for cathepsins and lysosomal membrane permeability was excluded. Autophagy is induced, but is not the mode of death and may act as a cell survival mechanism. There is no evidence of pure necrosis, while the presence of E3 11.6 does not modulate the mode or extent of cell death. Thus, E1A CR2-deleted oncolytic adenoviral cytotoxicity in ovarian cancer may define a novel mode of programmed cell death.
Figures
Figure 1
Activity of E1A CR2-deleted adenoviral vectors in ovarian cancer. (a) IGROV1 and OVCAR4 cells were infected with _dl_922-947, _dl_CR2 and _dl_CR2 tSmac (MOI 0.001-10000 plaque-forming unit (PFU) per cell). Cell viability was assessed 120 h later. Results are presented as percentage cell survival compared to mock-infected cells (mean±s.d. _n_=3). IC50 results are presented in tabular form. (b) IGROV1 cells were infected with _dl_922-947, _dl_CR2, _dl_CR2 tSmac and Ad LM-X (all MOI 10), mock-infected or incubated with cisplatin (10 μ
m
) in triplicate. After 72 h, caspase activation was measured using PhiPhi Lux-G1D2. (c) Following infection with _dl_922-947 (MOI 0.001-1000), IGROV1 cells were treated with zVAD-fmk (0-25 μ
m
). Cell viability was assessed 144 h later. (d) IGROV1 cells were treated with cisplatin (1 and 10 μ
m
) with and without 25 μ
m
zVAD-fmk. Cell survival was assessed after 72 h by MTT assay. ***P<0.001. (e) IGROV1 cells were harvested up to 120 h following infection with _dl_CR2 (MOI 10). About 20 μg of protein was separated on sodium dodecyl sulphate (SDS)-PAGE gels and analysed for expression of caspase-3, E1A and PARP by immunoblot.
Figure 2
Markers of classical apoptosis. (a) IGROV1 cells were infected with _dl_CR2 (MOI 10). Cell surface exposure of PS and loss of mitochondrial membrane permeability were analysed using Annexin V-FITC and TMRE over 120 h. DAPI-positive cells were gated out. (b) The presence of hypodiploid DNA in IGROV1 cells infected with _dl_CR2 (MOI 10) was assessed following incubation with PI. (c) Markers of classical apoptosis in IGROV1 cells treated with cisplatin (10 μ
m
) for 72 h are shown. PS, phosphatidylserine exposure, MMP, mitochondrial membrane potential loss and sub-G1, sub-G1 DNA levels. (d) IGROV1 cells were treated with _dl_922-947 (MOI 10), cisplatin (3 μ
m
) alone and in combination. After 72 h, cells were harvested and analysed for markers of apoptosis as above. (e) OVCAR4 and OVCAR4-Bcl-2 cells were infected with viruses (all MOI 10) or treated with cisplatin (10 μ
m
). Cell viability was assessed 72 h later. All results represent mean±s.d. _n_=3.
Figure 3
Assessment of non-classical apoptosis. (a) Following infection with _dl_CR2 (MOI 10), IGROV1 cells were treated with E64 cysteine protease inhibitor (0-100 μ
m
). Cell viability was assessed up to 144 h later by MTT assay (72 h results shown). Each bar represents normalized survival compared to mock-transfected cells at the same dose of E64; mean±s.d. _n_=3. (b) IGROV1 cells were infected with _dl_CR2 (MOI 10) or treated with cisplatin (10 μ
m
). After 72 h, lysosomal stability was assessed following AO staining.
Figure 4
Autophagy. (a) IGROV1 cells were prepared for TEM 72 h following infection with _dl_CR2 and Ad LM-X (both MOIs 3 and 10). Features of autophagy include increased numbers of lysosomes (closed arrow), the presence of autophagosomes with double membranes (open arrow). (b) IGROV1 cells were infected with _dl_922-947 (MOI 10) and imaged 48 h later following staining with monodansylcadaverine. (c) IGROV1 cells were co-infected with _dl_922-947 (MOI 10) and Ad GFP-LC3 (MOI 0.2) and assayed 72 h later for the formation of autophagosomes by confocal microscopy. As positive control, cells infected with Ad GFP-LC3 only were incubated in HBSS for 16 h prior to confocal imaging. (d) (i) IGROV1 cells were infected with _dl_CR2 (MOI 3 and 10) in the presence of 3-methyladenine (3MA; 0-100 μ
m
). Cell viability was assessed 72 h later. (ii) IGROV1 cells were infected with _dl_922-947 (MOI 0.03-300) and re-fed with 0-10 μ
m
chloroquine 3 h later. Cell survival was assayed 120 h later and results represent survival normalized for mock-transfected cells at each dose of chloroquine.
Figure 5
Cell architecture and necrosis. (a) Cells were infected with _dl_CR2 and imaged up to 72 h later under phase contrast microscopy. After 48 h, individual cells show membrane blebbing (solid arrow) and appear rounded (open arrow). By 72 h, widespread cell rounding and detachment is seen, but without disruption to cell membranes. (b) IGROV1 cells were infected with Ad LM-X (MOI 10) or _dl_CR2 (MOI 3 and 10) and prepared for TEM 72 h later. (i and ii) Mock-infected control cells; (iii) Ad LM-X (MOI 10); (iv and v) _dl_CR2 (MOI 10); (vi) _dl_CR2 (MOI 3). C, condensed chromatin; G, disrupted Golgi; M, mitochondria; N, nucleus; V, intra-nuclear virus assembly. (c) IGROV1 cells were infected with Ad LM-X, _dl_CR2 and _dl_CR2 tSmac (all MOI 10). Intracellular adenosine triphosphate (ATP) levels were measured 72 h later using a luciferase-based assay as detailed in the ‘Materials and methods’ section. Results represent mean±s.d., _n_=3.
Similar articles
- Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging.
Leyton J, Lockley M, Aerts JL, Baird SK, Aboagye EO, Lemoine NR, McNeish IA. Leyton J, et al. Cancer Res. 2006 Sep 15;66(18):9178-85. doi: 10.1158/0008-5472.CAN-06-1539. Cancer Res. 2006. PMID: 16982761 - A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B, Liu X, Fan J, Qi R, Bo L, Gu J, Qian Q, Qian C, Liu X. Li B, et al. J Gene Med. 2006 Oct;8(10):1232-42. doi: 10.1002/jgm.953. J Gene Med. 2006. PMID: 16900558 - Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
Bauerschmitz GJ, Guse K, Kanerva A, Menzel A, Herrmann I, Desmond RA, Yamamoto M, Nettelbeck DM, Hakkarainen T, Dall P, Curiel DT, Hemminki A. Bauerschmitz GJ, et al. Mol Ther. 2006 Aug;14(2):164-74. doi: 10.1016/j.ymthe.2006.01.010. Epub 2006 Mar 31. Mol Ther. 2006. PMID: 16580264 - Oncolytic adenovirus-induced autophagy: tumor-suppressive effect and molecular basis.
Tazawa H, Kagawa S, Fujiwara T. Tazawa H, et al. Acta Med Okayama. 2013;67(6):333-42. doi: 10.18926/AMO/52006. Acta Med Okayama. 2013. PMID: 24356717 Review. - Oncolytic adenoviruses for the treatment of brain tumors.
Gomez-Manzano C, Fueyo J. Gomez-Manzano C, et al. Curr Opin Mol Ther. 2010 Oct;12(5):530-7. Curr Opin Mol Ther. 2010. PMID: 20886384 Review.
Cited by
- Oncolytic virotherapy for hepatocellular carcinoma: A potent immunotherapeutic landscape.
Xiao R, Jin H, Huang F, Huang B, Wang H, Wang YG. Xiao R, et al. World J Gastrointest Oncol. 2024 Jul 15;16(7):2867-2876. doi: 10.4251/wjgo.v16.i7.2867. World J Gastrointest Oncol. 2024. PMID: 39072175 Free PMC article. - Oncolytic Adenovirus, a New Treatment Strategy for Prostate Cancer.
Yang K, Feng S, Luo Z. Yang K, et al. Biomedicines. 2022 Dec 15;10(12):3262. doi: 10.3390/biomedicines10123262. Biomedicines. 2022. PMID: 36552019 Free PMC article. Review. - Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction.
Mardi A, Shirokova AV, Mohammed RN, Keshavarz A, Zekiy AO, Thangavelu L, Mohamad TAM, Marofi F, Shomali N, Zamani A, Akbari M. Mardi A, et al. Cancer Cell Int. 2022 Apr 29;22(1):168. doi: 10.1186/s12935-022-02585-z. Cancer Cell Int. 2022. PMID: 35488303 Free PMC article. Review. - Carvedilol targets β-arrestins to rewire innate immunity and improve oncolytic adenoviral therapy.
Hoare JI, Osmani B, O'Sullivan EA, Browne A, Campbell N, Metcalf S, Nicolini F, Saxena J, Martin SA, Lockley M. Hoare JI, et al. Commun Biol. 2022 Feb 3;5(1):106. doi: 10.1038/s42003-022-03041-4. Commun Biol. 2022. PMID: 35115660 Free PMC article. - Autophagy in Tumor Immunity and Viral-Based Immunotherapeutic Approaches in Cancer.
Zahedi-Amiri A, Malone K, Beug ST, Alain T, Yeganeh B. Zahedi-Amiri A, et al. Cells. 2021 Oct 6;10(10):2672. doi: 10.3390/cells10102672. Cells. 2021. PMID: 34685652 Free PMC article. Review.
References
- Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature. 2005;434:658–662. - PubMed
- Bampton ET, Goemans CG, Niranjan D, Mizushima N, Tolkovsky AM. The dynamics of autophagy visualized in live cells: from autophagosome formation to fusion with endo/lysosomes. Autophagy. 2005;1:23–36. - PubMed
- Bauvy C, Gane P, Arico S, Codogno P, Ogier-Denis E. Autophagy delays sulindac sulfide-induced apoptosis in the human intestinal colon cancer cell line HT-29. Exp Cell Res. 2001;268:139–149. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- G84/6553/MRC_/Medical Research Council/United Kingdom
- G0601891/MRC_/Medical Research Council/United Kingdom
- G0601891(82080)/MRC_/Medical Research Council/United Kingdom
- C9423/A4119/CRUK_/Cancer Research UK/United Kingdom
- A4119/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Medical